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Introduction
Usher syndrome (USH) and nonsyndromic retinitis pigmentosa 
(NSRP) are forms of inherited retinal dystrophies. Usher syn-
drome is clinically and genetically heterogeneous and by far the 
most common cause of inherited deaf-blindness in man, with a 
prevalence of approximately 1 in 6,000 individuals.1 Based on 
the presence and progression of the clinical symptoms, Usher 
syndrome can be classified in three types: type 1 (USH1), type 
2 (USH2), and type 3 (USH3). Approximately two-third of Usher 
syndrome patients suffer from type 2 (ref. 2), of whom up to 
85% have mutations in USH2A.3 USH2 patients present with 
congenital hearing impairment, which can be partly compen-
sated by hearing aids or cochlear implants,4 and retinitis pig-
mentosa (RP). NSRP is more prevalent than Usher syndrome, 
occurring in 1 per 4,000 individuals worldwide,5 of whom up to 
23% can be explained by mutations in USH2A.6,7 Both USH2 
and NSRP patients with mutations in USH2A develop night 
blindness in their late teens as a consequence of photoreceptor 
degeneration.8 This night blindness subsequently progresses 
from peripheral vision loss towards legal blindness around the 
end of the sixth decade of life.9 However, USH2 patients have 
an earlier and faster decline of visual function as compared to 
NSRP patients with an USH2A mutation.10
Usher syndrome and other retinal dystrophies for long 
have been considered as incurable disorders. However, 
recent preclinical studies and ongoing phase 1/2 clinical tri-
als using gene augmentation therapy led to promising results 
in selected groups of Usher syndrome, Leber congenital 
amaurosis and retinitis pigmentosa patients carrying muta-
tions in MYO7A11–14 (ClinicalTrials.gov; NCT02065011) or 
RPE65 (refs. 15–18). However, USH2A gene augmentation 
is hampered as the size of its coding sequence (15,606 bp; 
Genbank NM_206933) exceeds the cargo capacity of the 
currently available vehicles used for delivery (e.g., adeno-
associated or lentiviral vectors). An alternative to gene 
augmentation is gene correction by for instance CRISPR/
Cas9-based targeted genome repair. Although promising 
preclinical advances have been made, gene repair is not yet 
fully developed for clinical applications.19
Mutations in USH2A are mostly private and so far more than 
600 different mutations have been reported which are distrib-
uted all over the gene (e.g., nonsense and missense mutations, 
deletions, duplications, large rearrangements, and variants 
that affect splicing (USHbases; http://www.lovd.nl/USH2A)).20,21 
However, there are a few mutations that originate from a com-
mon ancestor (e.g., c.2299delG; p.Glu767fs and c.2276G>T; 
p.Cys759Phe) and are therefore observed more frequently.21–23
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Usher syndrome (USH) is the most common cause of combined deaf-blindness in man. The hearing loss can be partly compensated 
by providing patients with hearing aids or cochlear implants, but the loss of vision is currently untreatable. In general, mutations 
in the USH2A gene are the most frequent cause of USH explaining up to 50% of all patients worldwide. The first deep-intronic 
mutation in the USH2A gene (c.7595-2144A>G) was reported in 2012, leading to the insertion of a pseudoexon (PE40) into the 
mature USH2A transcript. When translated, this PE40-containing transcript is predicted to result in a truncated non-functional 
USH2A protein. In this study, we explored the potential of antisense oligonucleotides (AONs) to prevent aberrant splicing of 
USH2A pre-mRNA as a consequence of the c.7595-2144A>G mutation. Engineered 2’-O-methylphosphorothioate AONs targeting 
the PE40 splice acceptor site and/or exonic splice enhancer regions displayed significant splice correction potential in both 
patient derived fibroblasts and a minigene splice assay for USH2A c.7595-2144A>G, whereas a non-binding sense oligonucleotide 
had no effect on splicing. Altogether, AON-based splice correction could be a promising approach for the development of a future 
treatment for USH2A-associated retinitis pigmentosa caused by the deep-intronic c.7595-2144A>G mutation.
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In 2012, the first deep-intronic mutation (c.7595-2144A>G) 
in USH2A was reported for which also an ancestral event was 
suggested in association with the rare variant c.6049+76A>T.24 
This mutation creates a high-quality splice donor site in intron 
40, resulting in the incorporation of a 152-bp pseudoexon 
(PE40) into the mature transcript24 and is predicted to lead to 
a premature termination of translation (p.Lys2532Thrfs*56). 
With a 4% frequency, this deep-intronic mutation represents 
the second most frequent Usher syndrome type 2A-causing 
mutation (Usher syndrome type 2A-patient cohort from Mont-
pellier (n = 562), unpublished data). Recently, three addi-
tional deep-intronic mutations were identified in USH2A,25 
emphasizing the contribution and frequency of deep-intronic 
mutations to the pathology of Usher syndrome. Subsequent 
diagnostic screening of the c.7595-2144A>G mutation in 
Usher syndrome patient cohorts identified multiple patients 
with the mutation in a homo- or compound heterozygous 
state.21,24,26–30 In addition, this mutation is reported (in trans 
to p.Arg4192His) in a patient with NSRP,26 suggesting a wide 
distribution of the c.7595-2144A>G mutation in both USH 
and NSRP patients.
In this study, we explored the potential of antisense oligonu-
cleotides (AONs) to redirect splicing in patient-derived fibro-
blasts harboring a heterozygous USH2A c.7595-2144A>G 
mutation. Both in fibroblasts and in a minigene splice assay, 
AONs showed promising preclinical potential to correct aber-
rant splicing, which might be of benefit for USH2A c.7595-
2144A>G patients in the future.
Results
The deep-intronic c.7595-2144A>G mutation in USH2A cre-
ates a high-quality splice donor site that leads to a partial 
exonification of intron 40 (152 bp; PE40) into the mature 
mRNA24 (Figure 1a,b). This results in a predicted frameshift 
and premature termination of translation. The aim of this 
study is to assess the effectiveness of AONs targeting the 
PE40 region thereby specifically induce PE40 skipping from 
USH2A pre-mRNA containing the c.7595-2144A>G mutation 
(Figure 1c).
Previous studies demonstrated highest exon-skipping 
efficiencies using AONs targeting exonic splice enhancer 
(ESE) motifs recognized by human SRSF2 (SC35), SRSF1 
(SF2/ASF) and SRSF5, instead of intron-exon boundaries or 
other types of splice enhancers.31,32 Hence, AONs have been 
designed (sequences in Table 1) encompassing most pre-
dicted SRSF2, SRSF1, and SRSF5 ESE sequence motifs. 
AON1 targets five predicted SRSF1, two SRSF2, five SRSF5, 
and two hexamer ESE sequences, while AON2 targets two 
SRSF2 and one SRSF5 motifs (Supplementary Figure S1). 
Guidelines for AON design further dictate that AONs should 
target partially open and partially closed pre-mRNA struc-
tures, which is the case for both AON1 (10 closed and 13 
open nucleotides) and AON2 (13 closed and 7 open nucleo-
tides). Thermodynamic criteria for AON design include a free 
energy higher than −4 kcal/mol for self-folding, a free energy 
higher than −15 kcal/mol for self-dimerisation and a prefer-
able binding energy higher than 20 kcal/mol.33 All these cri-
teria were met in the design of both AON1 and 2 (Table 1).
Fibroblasts from an USH2 patient, having the USH2A 
c.7595-2144A>G (p.Lys2532Thrfs*56) and c.10636G>A 
(p.Gly3546Arg) mutations in compound heterozygosity, were 
obtained in order to evaluate the splice correction potential 
of both AONs. In order to be able to detect PE40-contain-
ing USH2A transcripts, NMD inhibition using cycloheximide 
was needed (Supplementary Figure S2). Unexpectedly, 
without NMD inhibition also the USH2A allele containing the 
c.10636G>A (p.Gly3546Arg) missense mutation could not 
be amplified. This could be the result of quantity-associated 
detection problems or alternatively could be because the 
missense variant has an effect on splicing, resulting in an out 
of frame transcript that is subjected to NMD. However, after 
NMD inhibition, the presence of this mutation could be con-
firmed by sequence analysis whereas no indications for alter-
native splice events were obtained. Subsequent quantitative 
RT-PCR analyses revealed that the relative USH2A transcript 
levels in the patient-derived and control fibroblasts were 
0.12 ± 0.05 and 0.10 ± 0.03% as compared to the expres-
sion levels of the housekeeping gene GUSB, respectively. 
Because of the extremely low expression levels in fibroblasts, 
USH2A could only be detected after using a highly sensitive 
reverse transcriptase, as was already reported by others.27
USH2A transcripts from patient-derived fibroblasts were 
analyzed by RT-PCR using primers in exon 39 (forward) and 
exon 42 (reverse) which revealed the inclusion of PE40 in 
mature USH2A mRNA (Figure 2a), as expected. Transfection 
of these fibroblasts with either AON1, AON2 or with a cock-
tail of AON1+2 together in a final concentration of 0.5 µmol/l, 
resulted in a significant skipping of PE40 ( Figure 2a), whereas 
no aberrant splice events were observed when transfecting 
these AONs in control fibroblasts (Figure 2a). RT-qPCR analy-
ses showed that the total amount of USH2A transcripts was 
not significantly altered in AON-treated cells as compared to 
SON2-treated cells (AON1: P = 0.0797; AON2: P = 0.2039; 
AON1+2: P = 0.6491 (two-tailed Student’s t-test); Supplemen-
tary Figure S3), which indicates that the PE40-containing 
transcript is not degraded but instead is converted into the 
wild-type transcript as a consequence of AON-treatment. We 
next calculated the relative amount of PE40 incorporation into 
the USH2A transcript by comparing PCR fragment intensi-
ties on gel. The ratio of PE40 incorporation was calculated for 
every PCR product. Around half of the USH2A transcripts from 
untransfected patient fibroblasts contained PE40 (0.56 ± 0.03 
(ratio ± SEM) ( Figure 2b). We observed a minimal difference in 
the average ratio of PE40 incorporation between untransfected 
cells and cells transfected with a nonbinding sense oligonu-
cleotide (SON2; 0.44 ± 0.04) (P = 0.0216) (Figure 2b), which 
might be explained by natural variation as a consequence of 
low USH2A transcript levels. Patient fibroblasts transfected with 
either AON1 or AON2 separately (1 µmol/l), showed a signifi-
cantly lower average ratio of PE40 incorporation (0.15 ± 0.03; 
P < 0.0001 and 0.23 ± 0.04; P < 0.01, respectively) as com-
pared to SON2 (Figure 2b). Cotransfecting AON1+2 in a 1:1 
ratio with the same final concentration of 1 µmol/l resulted in 
the nearly complete exclusion of PE40 (0.08 ± 0.02; P < 0.0001 
when compared to SON2) (Figure 2b). AONs 1 and 2 thus 
both showed the ability to induce skipping of PE40 in patient-
derived fibroblasts, however the highest degree of splice cor-
rection was induced using a cocktail of AON1+2.
www.moleculartherapy.org/mtna
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Quantification of the splice redirection potential of the 
AONs using RT-qPCR analyses appeared to be technically 
challenging as a result of very low USH2A expression lev-
els in fibroblasts, especially in the case of compound het-
erozygous mutations. For this reason, we set up an in vitro 
minigene splice assay, based on the pCI-NEO plasmid 
 (Figure 3a).34 The genomic region of USH2A PE40 (both 
wild-type and mutant), surrounded by 722 bp up- and 636 bp 
downstream sequence, was cloned between RHO exons 3 
and 5 to model splice defects as seen in USH2A patients with 
the c.7595-2144A>G mutation. Indeed, as a consequence 
of the mutation,24,26 the mutant minigene splice assay only 
yielded a transcript consisting of RHO exon 3-USH2A PE40-
RHO exon 5 whereas the wild-type minigene splice assay 
only resulted in a transcript containing RHO exons 3 and 5 
(Figure 3b).
Using an USH2A PE40 minigene splice assay, we tried 
to induce PE40-skipping from the artificial RNA using the 
same AONs as used to transfect fibroblasts. Cotransfec-
tion of the PE40 mutant minigene (1 µg) with 0.5 µmol/l 
of either AON1 or AON2, resulted in both cases in a com-
bination of corrected and non-corrected transcripts (Fig-
ure 3b; 274 bp (corrected) versus 426 bp (noncorrected). 
Subsequent sequence analysis of the noncorrected PCR 
product derived from AON1-treated samples revealed that 
the first 12 bp of PE40 were lacking as a consequence of 
a second cryptic splice acceptor site use. This was neither 
observed in patient-derived fibroblasts treated with AON1 
nor in AON2-treated samples. In addition, the AON1-treated 
minigene splice assay displayed a faint intermediate splice 
product, most probably resulting from partially skipped 
PE40 (Figure 3b). Sequence analysis of the lower, pre-
sumably corrected fragment, showed that it indeed repre-
sents correct splicing of RHO exon 3 to exon 5. To exclude 
AON-induced effects on PE40 splicing independent of the 
targeted sequence, we reversed the sequence of AON2 
Figure 1 USH2A splicing and principle of AON-based splice correction. (a) In wild-type alleles, USH2A exons 40 and 41 are recognized 
and fused during splicing of USH2A pre-mRNA. (b) In case the c.7595-2144A>G mutation is present (indicated with an asterisk), a high-quality 
splice donor site is created. As a result, the 152 bp directly upstream are recognized as a pseudoexon and incorporated into USH2A mRNA 
(highlighted with a black background). (c) Addition of AONs complementary to PE40 can potentially prevent binding of splice factors to that 
region (indicated by a cross), thereby excluding PE40 from the mature USH2A transcript.
Transcription
Transcription
3′ 5′
TranscriptionPrevents binding
of splice factors
Splicing
Splicing
Splicing
a
b
c
Table 1 Sequences and thermodynamic properties of designed 2’-O- methylphosphorothioate AONs
Name Sequence Structure (kcal/mol) Self-dimerisation (kcal/mol) AON+target (kcal/mol)
AON1 5’-GUGUGAUUCUGGAGAGGAAGCUG-3’ −1.9 −7.6 41.8
AON2 5’-CCCUUAAAAGCCAGCAUACA-3’ 1.7 −5.0 30.1
SON2 5’-UGUAUGCUGGCUUUUAAGGG-3’ NA NA NA
AON, antisense oligonucleotide; NA, not applicable.
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into a sense orientation (SON2). Cotransfecting the PE40 
mutant minigene splice assay with the nonbinding SON2 
did not result in splice modulation of PE40, demonstrat-
ing the specificity of the result obtained with the antisense 
sequences (Figure 3c). These results were in total agree-
ment with the results obtained from AON-treated patient-
derived fibroblasts (Figure 2a,b). Since both AONs 1 and 2 
showed exon-skipping potential using the minigene splice 
assay, we next lowered AON concentrations ranging from 
1.0 to 0.01 µmol/l in order to determine the minimal con-
centration at which the AONs were still able to induce sig-
nificant PE40 splice redirection. As shown in Figure 4a,b, 
for both AON1 and AON2, we observed a gradual decrease 
of PE40-containing transcripts to coincide with increasing 
concentrations of AON. When cotransfecting AON1 and 
2 as a cocktail, a similar PE40-skipping effect was seen 
(Figure 4c). However, in contrast to what we observed for 
both AON1 and 2 individually, a steep turning point in splice 
redirection potential was seen between a total AON con-
centration of 0.1 and 0.05 µmol/l. In addition, we observed 
a decrease in target transcripts when applying AON1 at 
higher concentrations (0.5 or 1 µmol/l) to our minigene 
splice assay (Figure 4a), which we attributed as the result 
of toxicity.
In conclusion, we were able to show that designed AONs 
are able to induce PE40-skipping in both patient-derived 
fibroblasts and in vitro minigene splice assays.
Discussion
Mutations in USH2A that affect splicing are responsible for 
Usher syndrome type 2 and autosomal recessive retinitis 
pigmentosa. Recent identification of four deep-intronic muta-
tions leading to inclusion of PEs underlines the importance 
of this pathogenic mechanism,24,25 that was underestimated 
a few years ago. In this work, we used the c.7595-2144A>G 
mutation, which represents the second most frequent 
USH2A mutation in some populations, as a model to initi-
ate the development of an AON-based therapy for USH2A-
associated retinitis pigmentosa.
Mutations that affect pre-mRNA splicing represent a sig-
nificant fraction of disease-causing mutations, in a variety 
of inherited disorders.35,36 Different strategies have been 
employed to correct the resulting splice defects, of which 
AON treatment seems most promising. AONs do not alter 
endogenous transcription levels and also their relative ease 
in design and low production costs can be regarded favorable 
for AON-based therapies.35,37 The sequence-specific proper-
ties of AONs make them suitable for interfering with splic-
ing processes for different therapeutic purposes.38,39 Next to 
skipping of (pseudo)exons, AONs have been shown to be 
able to retain exons that are skipped as a consequence of 
splice site mutations.40,41 In addition, AONs can be used to 
alter the ratio between two naturally occurring alternatively 
spliced transcripts.38
Figure 2 AON-based splice correction in patient-derived fibroblasts. (a) One representative sample of each AON treatment is shown, 
both for patient-derived and control fibroblasts (upper panel). The upper band represents USH2A containing PE40, whereas the lower band is 
USH2A lacking PE40. ACTB amplification is shown as a loading control (lower panel). (b) For every PCR analysis the PE40/(PE40+USH2A 
lacking PE40) transcript ratio was calculated from the gel intensities of PCR products normalized for their fragment length and plotted as a dot, 
with the mean ratio represented by a horizontal line. Samples in which the USH2A transcript lacking PE40 was not amplified were excluded 
from calculations, which was the case for four datapoints (one in both AON2 and SON2 and two in the non-AON treated cells). An unpaired 
two-tailed Student’s t-test was used to compare calculated ratios between AON-treated and SON-treated patient-derived fibroblasts, showing 
a significant reduction of PE40 incorporation in all three AON treatment (AON1, AON2, and AON1+2) conditions (indicated by ***(P < 0.001) 
or **(P < 0.01)). Grey error bars: SEM; NTC: negative template control; U: untreated control; a.u.: arbitrary units.
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Figure 3 USH2A PE40 minigene splice assay to assess AON efficacy in vitro. (a) Schematic representation of the minigene splice 
assay, with the nucleotide corresponding to the USH2A c.7595-2144A>G substitution highlighted with an asterisk. The genomic USH2A 
PE40 sequence (indicated with a black background “USH2A PE40”) and flanking sequences (indicated with a fat black line) were cloned 
between RHO exons 3 and 5. Targeting sequence of AON1 and AON2 is schematically indicated above the USH2A PE40 region. (b) RT-PCR 
analysis of RHO ex3-USH2A PE40 wild-type/mutant-RHO ex5 RNAs, isolated from transfected HEK293T cells that were cultured in the 
absence or presence of AON1, AON2, or AON1 and 2 together. AONs are directed against the aberrant USH2A PE40 exon and used in a final 
concentration of 0.5 µmol/l. The upper bands represent the aberrant RHO-USH2A PE40 splice product (426 or 414 bp when AON1-treated), 
whereas the lower bands represent the corrected transcript without USH2A PE40 (274 bp). Also an intermediate splice product was observed 
after AON1 treatment. SON2 is a nonbinding control sense oligonucleotide and cotransfection into HEK293T cells with the minigene splice 
assay only gives rise to the aberrant splice product. Water (mQ) was used as a negative control.
CMV RHO exon3 RHO exon5
RHO exon3 RHO exon5
USH2A PE40
RHO exon3 RHO exon5USH2A PE40
RHO exon3 RHO exon5
RHO exon3 RHO exon5
USH2A PE40
[A/G*]
PE40 mutPE40 wt
500
− − +AON1 +AON2 +AON1+2 SON2 mQ
400
300
AON1 AON2
(426 bp)(274 bp)
a
b
Figure 4 Dose-dependent AON-induced splice correction of USH2A using a minigene splice assay. RT-PCR analysis of RHO ex3-
USH2A PE40 mutant-RHO ex5 transcripts isolated from transfected HEK293T cells that were cultured in the absence or presence of different 
end-concentrations of AON1 (a), AON2 (b), or AON1+2 (c), ranging from 0 to 1.0 µmol/l. PCR (30 cycles) was performed from RHO exon 
3 to exon 5, in order to specifically amplify minigene splice assay derived cDNA. The lower band (274 bp) represents the transcript without 
USH2A PE40.
RHO exon3 RHO exon5
(426 bp)
(274 bp)
RHO exon3 RHO exon5
USH2A PE40
RHO exon3 RHO exon5
(426 bp)
(274 bp)
RHO exon3 RHO exon5
USH2A PE40
RHO exon3 RHO exon5
(426 bp)
(274 bp)
RHO exon3 RHO exon5
USH2A PE40
WT
600
500
400
300
200
600
500
400
300
200
600
500
400
300
200
0 0.01 0.02 0.05
Concentration AON1 (µmol/l)
Concentration AON2 (µmol/l)
Total concentration AON1+2 (µmol/l)
0.1 0.2 0.5 1.0
0 0.01 0.02 0.05 0.1 0.2 0.5 1.0
0 0.01 0.02 0.05 0.1 0.2 0.5 1.0
a
b
c
Molecular Therapy—Nucleic Acids
Antisense Oligonucleotide-based Splice Correction for USH2A-associated Retinal Degeneration
Slijkerman et al.
6
Several preclinical proof-of-concept studies for AON-based 
RNA splice modulation therapy have been performed, show-
ing promising results for different genetic disorders such as 
Leber congenital amaurosis, Hutchinson-Gilford progeria syn-
drome, spinal muscular atrophy or Duchenne muscular dys-
trophy.31,42–48 As a consequence, AONs are now in or beyond 
different phase 1, 2, or 3 clinical trials to evaluate their thera-
peutic potential and biosafety.49–51 No major adverse effects 
have been observed in patients with Duchenne muscular dys-
trophy after subcutaneous injections with Drisapersen, how-
ever mild-to-moderate reactions at the site of injection and 
proteinuria have been observed in most cases.52 Increasing 
doses of Drisapersen above 6 mg/kg are less well tolerated 
and lead to inflammatory responses.53 The phosphorothioate 
backbone can be immunostimulatory mainly via the nucleic 
acid recognizing toll like receptors (TLRs) 3, 7, 8 and 9 (ref. 
54). Although not proven, direct delivery into the eye will most 
probably circumvent systemic exposure of AONs to TLRs 
due to the presence of a blood-retinal barrier, however, TLR3 
expression has also been observed in retinal pigment epi-
thelium cells.55 2’-O-methyl modification of the riboses within 
the phosphorothioate backbone has been described to pre-
vent activation of TLR7-9, but not of TLR3 (ref. 56). As TLR3 
recognizes double stranded DNA,56 it is not expected that a 
TLR3-activated inflammatory response will be induced upon 
an intraocular delivery of AONs.57
Different guidelines to aid AON design have been 
described by others.33,37 AONs complementary to exonic 
splice enhancer (ESE) motifs that are targeted by Ser-Arg-
rich splice modulators, in particular SRSF1 (SF2/ASF), 
SRSF2 (formerly known as SC35) and SRSF5, have been 
shown to be most effective in exon skipping.37 Also, it has 
been shown that effective AONs often bind close to the 
splice acceptor site and the free energy of the AON-target 
complex is higher than that of the target complex and that 
of the AON individually.37 By adopting these guidelines we 
have designed two different AONs and examined the exon-
skipping potential after single AON addition or after addition 
of a cocktail consisting of the two AONs. AON1 has been 
designed to target five predicted SRSF1, two SRSF2, five 
SRSF5, and two hexamer ESE sequence motifs, thereby 
overlapping the PE40 splice acceptor site. The use of AON1 
in combination with a minigene splice assay results in the use 
of an alternative splice acceptor site 12 bp downstream of the 
regular PE40 splice acceptor site. Although this effect has 
not been observed in fibroblasts treated with AON1 and/or 
AON2, we cannot rule out that, due to the low level of USH2A 
expression, we are unable to detect any alternatively spliced 
transcripts. In line with other studies, suggesting that the use 
of a cocktail of AONs is often more potent than using a single 
AON,58–60 our results show that a combination of AON1+2 is 
indeed more potent than using either AON individually.
In our study, we show USH2A splice correction in biologi-
cally nonrelevant patient-derived fibroblasts and minigene 
splice assays. However, this does not result in the produc-
tion of functional USH2A protein. In order to evaluate the 
effect of AON-induced splice correction on the level of pho-
toreceptor maintenance and function, physiological relevant 
cellular and/or animal models will be crucial. Using iPSC 
technology, it is possible to generate photoreceptor-like 
cells from patient-derived keratinocytes or fibroblasts, which 
has already been shown for an USH2A patient having the 
c.7595-2144A>G mutation in compound heterozygosity with 
the c.12575G>A; p.Arg4192His mutation.26 The use of pho-
toreceptor-like cells will enable the assessment of potential 
AON-induced off-target effects by sequencing total RNA from 
those artificial eyecups. For the evaluation of visual function, 
animal models will be essential. However, the currently avail-
able Ush2a knockout mouse model only shows a mild reti-
nal degeneration with a very late age of onset.61 Zebrafish 
can be an attractive alternative model for studying Usher 
syndrome-related retinal degeneration.62 Electroretinogram 
(ERG) traces have been shown to be significantly attenuated 
in zebrafish Myo7a (USH1b), Ush1c (USH1c), and Pcdh15b 
(USH1f) mutants and morphants.63–65 In addition, morpholino-
induced knockdown of zebrafish Ush2a results in moderate 
levels of early-onset photoreceptor degeneration in larvae (5 
days postfertilization).66 Although the effect of human muta-
tions on splicing is not always recapitulated in non-human 
species,67 the c.7595-2144A>G mutation results in a con-
sensus (“GTAAG”) splice donor site. Recent advances in 
CRISPR/Cas9 technology now enable the generation of a 
humanized locus for the USH2A PE40 intronic sequence in 
zebrafish. Future research will determine whether the effect 
of the c.7595-2144A>G mutation is recapitulated in a human-
ized zebrafish, and whether this model will be suitable to 
evaluate the effect of AON-induced splice correction on the 
level of visual function.
Once an animal model is present, the next challenge will 
be the delivery of AONs to photoreceptor cells. Systemic 
drug administration is one possible route for treating retinal 
disorders. However, retinal transfer of drugs from the circu-
lating blood is strictly regulated by two blood–ocular barrier 
systems, the blood–aqueous barrier and the blood-retinal 
barrier.45,68,69 In order to effectively overcome these physical 
barriers, AONs need to be delivered directly into the human 
eye, either via injections of naked AONs into the vitreous 
humor or by using a stabilizing vehicle (e.g., recombinant 
virus, designed nanoparticles, cell penetrating peptides, exo-
somes, or liposomes).35,70,71 Once present in the eye, naked 
AONs have proven to be able to freely diffuse into all cells 
of the retina to interfere with splicing.45 When using naked 
AONs, it will be needed to repeatedly supplement photore-
ceptor cells with AONs, since effectiveness will be lost over 
time due to AON degradation or wash out. Intravitreal injec-
tions in mice have demonstrated that 2’-O-methylphosphoro-
thioate AONs are effective in photoreceptor cells for at least 
1 month and probably longer.45 Therefore, we speculate that 
patients will need a few intravitreal AON administrations per 
year.
A durable splice correction effect is likely to be achieved by 
administration of an AAV vector expressing AON sequences 
linked to a modified U7 small nuclear RNA (U7 snRNA). Via 
this route, it will be possible to induce the same therapeutic 
effect as with naked AONs, but presumably with a long-last-
ing effect.72–74 However, traditionally AAVs are unable to cross 
the retinal layers from vitreous humor into photoreceptor cells 
due to the presence of a diffusive barrier made up by the 
inner limiting membrane.75 In addition, also the presence of 
neutralizing antibodies may reduce successful photoreceptor 
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infection from intravitreally injected AAVs.76 For this reason, 
AAVs will need to be injected subretinally, limiting the tar-
geted retinal area.77 However, a recent study presented a 
promising rAAV serotype which can be efficiently delivered 
intravitreally.78 After transduction, the rAAV DNA strands will 
form very stable episomal structures, from which transcrip-
tion can take place. Since photoreceptor cells are nondivid-
ing cells, integration in their genome is not a pre-requisite for 
success and therefore the use of rAAVs instead of integrating 
(retro)viruses will lower the risk of potential side effects with-
out reducing AON effectiveness.
Besides presenting with retinal degeneration, Usher syn-
drome patients suffer from congenital hearing impairment. 
Usher proteins have been shown to be the structural com-
ponents of the fibrous links between hair cell stereocilia 
and essential for proper hair bundle formation and function 
(reviewed by Kremer et al.79). USH1C encodes harmonin, a 
protein directly connected to the USH2A protein in both hair 
cells and photoreceptors.80 Treatment of an Ush1c mouse 
model with splice modulating AONs anytime during the first 
thirteen days after birth, results in a restored orientation and 
function of cochlear hair bundles.81 Treatment on this mouse 
from post-natal day 16 onwards, which corresponds to 5 
months of gestation in humans, shows no beneficial effects 
anymore. Therefore, AON-based splice correction will prob-
ably only be effective when administered during or prior to 
the development of inner ear hair bundles.
In conclusion, this study shows that administration of 
engineered AONs to fibroblasts of an individual affected by 
Usher syndrome almost fully restores a splice defect that is 
caused by the frequent deep-intronic c.7595-2144A>G muta-
tion in USH2A. Although promising on transcript level, future 
research is needed to determine the therapeutic potential of 
AON-based splice correction as a treatment to stop or slow-
down the progression of this devastating blinding aspect of 
Usher syndrome and isolated USH2A-associated retinitis 
pigmentosa.
Materials and methods
Antisense oligonucleotides. The sequence of USH2A PE40 
was analyzed for the presence of exonic splice enhancer 
motifs using the online ESE finder 3.0 program (http://rulai.
cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home) 
with standard settings. The presence of RESCUE-ESE sites 
was determined using the RESCUE-ESE tool (http://genes.
mit.edu/burgelab/rescue-ese/). AONs were subsequently 
designed to each cover multiple SRSF1, SRSF2, SRSF5, or 
hexamers in PE40. Furthermore, the energetically most stable 
secondary structure of USH2A PE40 (including 25 nucleotides 
of flanking sequence both up- and downstream) was predicted 
using the RNAStructure software (http://rna.urmc.rochester.
edu/rnastructure.html).82 In addition, we picked sequences to 
be targeted by AONs predicted as “partially open”. With the 
same webtool, also thermodynamic criteria were evaluated: 
free energy of the AON, of the AON-AON complexes and of 
binding energy between the AON and its target sequence.33 
AONs according above criteria were designed with a T
m
 of 
58 °C and a GC% between 40–60%. The uniqueness of the 
AON target sequences was determined by BLAST analysis. 
The two most optimal AONs were purchased from Eurogen-
tec (Liège, Belgium) containing 2’-O-methyl modified riboses 
and a phosphorothioate backbone (sequences are presented 
in Table 1). As a nonbinding control, a sense orientation of 
AON2 was also acquired (named SON2). AONs were dis-
solved in phosphate-buffered saline (PBS) before use.
USH2A qPCR analysis. Total RNA was isolated from fibro-
blasts using the Nucleospin RNA II isolation kit (MACH-
EREY-NAGEL #740955.50, Düren, Germany), according 
to manufacturer’s protocol. Subsequently, 0.5–1.0 µg of 
total RNA was used for cDNA synthesis with SuperScript 
III RT (Life Technologies, #11755050, Carlsbad, CA). 
USH2A was subsequently amplified using forward primer 
5’-CCAGGGAAAAGAGCAGAGTG-’3 (exon 28) and reverse 
primer 5’-GATAGCCTCGCATGAAGGAG-3’ (exon 29). The 
housekeeping gene GUSB was used as a reference using the 
forward primer 5’-AGAGTGGTGCTGAGGATTGG-’3 (exon 2) 
and reverse primer 5’-GACACGCTAGAGCATGAGGG-3’ 
(exon 3). GoTaq (Promega A6001) was used to amplify 
USH2A and GUSB cDNA in triplicate in a 7500 HT qPCR 
machine. Analysis of the qPCR data was performed with 7500 
software (version 2.3), with the CT-threshold set manually. 
Subsequently, USH2A/GUSB ratios were calculated to obtain 
relative USH2A transcript levels.
Minigene splice assays. A plasmid containing the genomic 
region of RHO encompassing exons 3–5 inserted at the 
EcoRI/SalI sites in the pCI-NEO vector34 was adapted to the 
Gateway cloning system, as previously described.83 Using 
Gateway cloning technology, human USH2A PE40 (wild-type 
and mutant) together with 722 bp of 5’-flanking and 636 bp of 
3’-flanking intronic sequence was inserted in the vector.
Cell culture. HEK293T cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM)(Sigma-Aldrich D0819, 
St. Louis, MO) supplemented with 10% (v/v) fetal bovine 
serum (Sigma-Aldrich F7524) and 1% penicillin-strepto-
mycin (Sigma-Aldrich P4333). Cells were passaged twice 
a week. Primary fibroblasts of an USH2 patient, with com-
pound heterozygous USH2A mutations (c.7595-2144A>G 
and c.10636G>A), were cultured in DMEM (Sigma-Aldrich 
D0819) supplemented with 20% fetal bovine serum (Sigma-
Aldrich F7524), 1% sodium pyruvate (Sigma-Aldrich S8636) 
and 1% penicillin-streptomycin (Sigma-Aldrich P4333). Cells 
were passaged twice a week.
Transfection of AONs in patient-derived fibroblasts. Fibro-
blasts were seeded at a concentration of 5.0 × 105 cells/
well in a 12-well plate. Cells were subsequently transfected 
with AONs using FuGENE HD Transfection Reagent (Pro-
mega, #E2311, Madison, WI) according to manufacturer’s 
instructions, in quintuplicate. Twenty-four hours after trans-
fection, cells were treated for an additional 16 hours with 
cycloheximide (Sigma-Aldrich, #C4859—final concentra-
tion of 100 µg/ml in DMEM medium with all supplements as 
described before) prior to RNA isolation in order to inhibit 
nonsense-mediated decay of the USH2A PE40-containing 
transcripts.
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Transfection of AONs and minigene splice assay in HEK293T 
cells. One day before transfection, 5.0 × 105 HEK293T cells 
were seeded in each well of a 12-well plate, in a total volume 
of 0.9 ml medium containing all supplements as described 
before. Transfection mixtures were prepared by combining 1 
µl AON in a desired concentration as indicated in the graphs, 
500 ng of plasmid DNA and 45 µl polyethylenimine transfec-
tion reagent (PEI). Mixtures were incubated at room tem-
perature for 10 minutes, before being dropwise added to the 
cells. Forty-eight hours after transfection, cells were collected 
using a cell scraper and washed with 1x PBS prior to RNA 
isolation.
RNA isolation and RT-PCR. Total RNA was isolated from trans-
fected HEK293T or fibroblasts using the Nucleospin RNA II 
isolation kit (MACHEREY-NAGEL #740955.50, Düren, Ger-
many), according to manufacturer’s protocol. Subsequently, 
0.5–1.0 µg of total RNA was used for cDNA synthesis with 
iScript cDNA synthesis kit (Bio-Rad, #170–8891) or Super-
Script III RT (Life Technologies, #11755050) for HEK293T 
and primary fibroblasts respectively. For the splice correction 
experiments with the minigene splice assay, part of the cDNA 
was amplified under standard PCR conditions using Q5 poly-
merase (New England Biolabs, #M0491L, Ipswich, MA) and 
using forward primer 5’-CGGAGGTCAACAACGAGTCT-3’ 
and reverse primer 5’-AGGTGTAGGGGATGGGAGAC-3’ that 
are designed for exons 3 and 5 of the human RHO gene, 
respectively. For the splice correction experiments in fibro-
blasts, part of the USH2A cDNA was amplified under stan-
dard PCR conditions using Q5 polymerase and the primers 
5’-GCTCTCCCAGATACCAACTCC-3’ and 5’-GATTCACAT-
GCCTGACCCTC-3’ designed for exons 39 and 42, respec-
tively. A PCR amplifying ACTB cDNA using forward primer 
5’-ACTGGGACGACATGGAGAAG-3’ and reverse primer 
5’-CTTCACCACCACAGCTGAGA-3’ was employed as a con-
trol for the amount of lysed cell material. Every cDNA sample 
was analysed in quintuplicate, yielding in total 25 datapoints 
per AON. PCR products were separated on a 1.5% aga-
rose gel. Fragments presumably representing correctly and 
aberrantly spliced USH2A were excised from the gel, puri-
fied using Nucleospin Extract II isolation kit (MACHEREY-
NAGEL, #740609.250) and sequenced from both strands 
with the ABIPRISM Big Dye Terminator Cycle Sequencing 
V2.0 Ready Reaction kit and the ABIPRISM 3730 DNA ana-
lyzer (Applied Biosystems, Foster City, CA).
Quantification of PCR product intensities and ratio calcula-
tion. PCR products were size separated on a 1% agarose 
gel, and DNA was visualized using ethidium bromide. Gels 
were photographed with an Isogen Life sciences imager 
using ProXima AQ-4 (v3.0) software and subsequently quan-
tified with ImageJ (v1.46r) software. Both PE40-containing 
fragments and USH2A fragments lacking PE40 were covered 
in a square with an equal surface area, from which the inten-
sity profile was subsequently generated. The peaks’ bases 
were closed manually by drawing a horizontal line, after 
which the surface of the peaks was calculated, represent-
ing USH2A PE40-containing transcripts and transcripts lack-
ing PE40. These values were transferred to Microsoft Excel 
2007 and normalized for their product size (i.e., 1,052 or 
900 bp). The total amount of USH2A transcripts (i.e., the sum 
of PE40-containing and PE40-lacking band intensities) and 
the PE40 transcript ratio (i.e., PE40-containing transcripts 
divided by total USH2A transcripts) was calculated per con-
dition. Samples in which the USH2A transcript lacking PE40 
was not amplified were excluded from calculations, which 
was the case for four PCR products (one in both AON2 and 
SON2 and two samples in the non-AON-treated cells). Each 
gel image was analyzed twice, from which the average was 
plotted in a dot-plot using GraphPad Prism (v5.03, GraphPad 
Software, San Diego, CA). Statistical analyses were subse-
quently performed with a two-tailed unpaired Student’s t-test 
using GraphPad Prism.
Supplementary material
Figure S1. Predicted ESE sequence motifs in USH2A PE40.
Figure S2. Cycloheximide treatment induces stabilization of 
PE40 containing transcripts.
Figure S3. Quantification of total USH2A transcript level after 
AON treatment of fibroblasts.
Acknowledgments The authors would like to thank the 
CIBERER biobank (Valencia, Spain) for sharing USH2A 
patient-derived primary fibroblasts. This work is financially 
supported by the Dutch Organisation for Scientific research 
(NWO Veni grant 016.136.091; E.V.W.), the Dutch Organisa-
tion for Health Research and Development (ZonMW E-rare 
grant “Eur-USH” 40-42900-98-1006; E.V.W.), the Dutch eye 
foundations (Stichting Nederlands Oogheelkundig Onder-
zoek, SAFDOR and Stichting Blindenhulp; E.V.W. and H.K.), 
the French national union of blind and visually impaired 
people (UNADEV; A-FR), and the French National Research 
Agency (E-rare grant “Eur-USH” ANR-12-RARE-006-03; CV). 
The work in this manuscript has been patented under num-
ber PCT/EP2015/065736. E.V.W. reports being employed 
by Radboudumc and inventor on this patent. Radboudumc 
has licensed the rights to the patent exclusively to ProQR 
Therapeutics. As the inventor, E.V.W. is entitled to a share of 
any future royalties paid to Radboudumc, should the therapy 
eventually be brought to the market.
 1. Kimberling, WJ, Hildebrand, MS, Shearer, AE, Jensen, ML, Halder, JA, Trzupek, K et al. 
(2010). Frequency of Usher syndrome in two pediatric populations: Implications for genetic 
screening of deaf and hard of hearing children. Genet Med 12: 512–516.
 2. Millán, JM, Aller, E, Jaijo, T, Blanco-Kelly, F, Gimenez-Pardo, A and Ayuso, C (2011). An 
update on the genetics of usher syndrome. J Ophthalmol 2011: 417217.
 3. Yan, D and Liu, XZ (2010). Genetics and pathological mechanisms of Usher syndrome. 
J Hum Genet 55: 327–335.
 4. Sadeghi, AM, Cohn, ES, Kimberling, WJ, Halvarsson, G and Möller, C (2013). Expressivity 
of hearing loss in cases with Usher syndrome type IIA. Int J Audiol 52: 832–837.
 5. Hartong, DT, Berson, EL and Dryja, TP (2006). Retinitis pigmentosa. Lancet 368: 
1795–1809.
 6. Seyedahmadi, BJ, Rivolta, C, Keene, JA, Berson, EL and Dryja, TP (2004). 
Comprehensive screening of the USH2A gene in Usher syndrome type II and non-
syndromic recessive retinitis pigmentosa. Exp Eye Res 79: 167–173.
 7. McGee, TL, Seyedahmadi, BJ, Sweeney, MO, Dryja, TP and Berson, EL (2010). Novel 
mutations in the long isoform of the USH2A gene in patients with Usher syndrome type II 
or non-syndromic retinitis pigmentosa. J Med Genet 47: 499–506.
 8. Blanco-Kelly, F, Jaijo, T, Aller, E, Avila-Fernandez, A, López-Molina, MI, Giménez, A 
et al. (2015). Clinical aspects of Usher syndrome and the USH2A gene in a cohort of 433 
patients. JAMA Ophthalmol 133: 157–164.
 9. Sandberg, MA, Rosner, B, Weigel-DiFranco, C, McGee, TL, Dryja, TP and Berson, EL 
(2008). Disease course in patients with autosomal recessive retinitis pigmentosa due to 
the USH2A gene. Invest Ophthalmol Vis Sci 49: 5532–5539.
www.moleculartherapy.org/mtna
Antisense Oligonucleotide-based Splice Correction for USH2A-associated Retinal Degeneration
Slijkerman et al.
9
 10. Pierrache, LH, Hartel, BP, van Wijk, E, Meester-Smoor, MA, Cremers, FP, de Baere, E 
et al. (2016). Visual prognosis in USH2A-associated retinitis pigmentosa is worse 
for patients with Usher syndrome type IIa than for those with nonsyndromic Retinitis 
Pigmentosa. Ophthalmology 123: 1151–1160.
 11. Hashimoto, T, Gibbs, D, Lillo, C, Azarian, SM, Legacki, E, Zhang, XM et al. (2007). 
Lentiviral gene replacement therapy of retinas in a mouse model for Usher syndrome type 
1B. Gene Ther 14: 584–594.
 12. Lopes, VS, Boye, SE, Louie, CM, Boye, S, Dyka, F, Chiodo, V et al. (2013). Retinal gene 
therapy with a large MYO7A cDNA using adeno-associated virus. Gene Ther 20: 824–833.
 13. Colella, P, Trapani, I, Cesi, G, Sommella, A, Manfredi, A, Puppo, A et al. (2014). Efficient 
gene delivery to the cone-enriched pig retina by dual AAV vectors. Gene Ther 21: 450–456.
 14. Zallocchi, M, Binley, K, Lad, Y, Ellis, S, Widdowson, P, Iqball, S et al. (2014). EIAV-
based retinal gene therapy in the shaker1 mouse model for usher syndrome type 1B: 
development of UshStat. PLoS One 9: e94272.
 15. Bainbridge, JW, Smith, AJ, Barker, SS, Robbie, S, Henderson, R, Balaggan, K et al. 
(2008). Effect of gene therapy on visual function in Leber’s congenital amaurosis.  
N Engl J Med 358: 2231–2239.
 16. Cideciyan, AV,  Aleman, TS, Boye, SL, Schwartz, SB, Kaushal, S, Roman, AJ et al. 
(2008). Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle 
of vision but with slow rod kinetics. Proceed Natl Acad Sci USA 105, 15112–15117.
 17. Hauswirth, WW, Aleman, TS, Kaushal, S, Cideciyan, AV, Schwartz, SB, Wang, L et al. 
(2008). Treatment of leber congenital amaurosis due to RPE65 mutations by ocular 
subretinal injection of adeno-associated virus gene vector: short-term results of a phase I 
trial. Hum Gene Ther 19: 979–990.
 18. Maguire, AM, Simonelli, F, Pierce, EA, Pugh, EN Jr, Mingozzi, F, Bennicelli, J et al. (2008). 
Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med 358: 
2240–2248.
 19. Savić, N and Schwank, G (2016). Advances in therapeutic CRISPR/Cas9 genome editing. 
Transl Res 168: 15–21.
 20. Roux, AF, Faugère, V, Vaché, C, Baux, D, Besnard, T, Léonard, S et al. (2011). Four-year 
follow-up of diagnostic service in USH1 patients. Invest Ophthalmol Vis Sci 52: 4063–4071.
 21. Baux, D, Blanchet, C, Hamel, C, Meunier, I, Larrieu, L, Faugère, V et al. (2014). 
Enrichment of LOVD-USHbases with 152 USH2A genotypes defines an extensive 
mutational spectrum and highlights missense hotspots. Hum Mutat 35: 1179–1186.
 22. Aller, E, Larrieu, L, Jaijo, T, Baux, D, Espinós, C, González-Candelas, F et al. (2010). 
The USH2A c.2299delG mutation: dating its common origin in a Southern European 
population. Eur J Hum Genet 18: 788–793.
 23. Pennings, RJ, Te Brinke, H, Weston, MD, Claassen, A, Orten, DJ, Weekamp, H et al. 
(2004). USH2A mutation analysis in 70 Dutch families with Usher syndrome type II. Hum 
Mutat 24: 185.
 24. Vaché, C, Besnard, T, le Berre, P, García-García, G, Baux, D, Larrieu, L et al. (2012). 
Usher syndrome type 2 caused by activation of an USH2A pseudoexon: implications for 
diagnosis and therapy. Hum Mutat 33: 104–108.
 25. Liquori, A, Vaché, C, Baux, D, Blanchet, C, Hamel, C, Malcolm, S et al. (2016). Whole 
USH2A gene sequencing identifies several new deep intronic mutations. Hum Mutat 37: 
184–193.
 26. Tucker, BA, Mullins, RF, Streb, LM, Anfinson, K, Eyestone, ME, Kaalberg, E et al. (2013). 
Patient-specific iPSC-derived photoreceptor precursor cells as a means to investigate 
retinitis pigmentosa. Elife 2: e00824.
 27. Steele-Stallard, HB, Le Quesne Stabej, P, Lenassi, E, Luxon, LM, Claustres, M, Roux, AF 
et al. (2013). Screening for duplications, deletions and a common intronic mutation detects 
35% of second mutations in patients with USH2A monoallelic mutations on Sanger 
sequencing. Orphanet J Rare Dis 8: 122.
 28. Krawitz, PM, Schiska, D, Krüger, U, Appelt, S, Heinrich, V, Parkhomchuk, D et al. 
(2014). Screening for single nucleotide variants, small indels and exon deletions with a 
next-generation sequencing based gene panel approach for Usher syndrome. Mol Genet 
Genomic Med 2: 393–401.
 29. Aparisi, MJ, Aller, E, Fuster-García, C, García-García, G, Rodrigo, R, Vázquez-
Manrique, RP et al. (2014). Targeted next generation sequencing for molecular diagnosis 
of Usher syndrome. Orphanet J Rare Dis 9: 168.
 30. Sodi, A, Mariottini, A, Passerini, I, Murro, V, Tachyla, I, Bianchi, B et al. (2014). MYO7A 
and USH2A gene sequence variants in Italian patients with Usher syndrome. Mol Vis 20: 
1717–1731.
 31. Collin, RW, den Hollander, AI, van der Velde-Visser, SD, Bennicelli, J, Bennett, J and 
Cremers, FP (2012). Antisense oligonucleotide (AON)-based therapy for Leber congenital 
amaurosis caused by a frequent mutation in CEP290. Mol Ther Nucleic Acids 1: e14.
 32. Aartsma-Rus, A, Houlleberghs, H, van Deutekom, JC, van Ommen, GJ and ‘t Hoen, PA 
(2010). Exonic sequences provide better targets for antisense oligonucleotides than 
splice site sequences in the modulation of Duchenne muscular dystrophy splicing. 
Oligonucleotides 20: 69–77.
 33. Aartsma-Rus, A (2012). Overview on AON design. Methods Mol Biol 867: 117–129.
 34. Gamundi, MJ, Hernan, I, Muntanyola, M, Maseras, M, López-Romero, P, Alvarez, R et al. 
(2008). Transcriptional expression of cis-acting and trans-acting splicing mutations cause 
autosomal dominant retinitis pigmentosa. Hum Mutat 29: 869–878.
 35. Hammond, SM and Wood, MJ (2011). Genetic therapies for RNA mis-splicing diseases. 
Trends Genet 27: 196–205.
 36. Wang, GS and Cooper, TA (2007). Splicing in disease: disruption of the splicing code and 
the decoding machinery. Nat Rev Genet 8: 749–761.
 37. Aartsma-Rus, A, van Vliet, L, Hirschi, M, Janson, AA, Heemskerk, H, de Winter, CL et al. 
(2009). Guidelines for antisense oligonucleotide design and insight into splice-modulating 
mechanisms. Mol Ther 17: 548–553.
 38. Siva, K, Covello, G and Denti, MA (2014). Exon-skipping antisense oligonucleotides to 
correct missplicing in neurogenetic diseases. Nucleic Acid Ther 24: 69–86.
 39. Gerard, X, Garanto, A, Rozet, JM and Collin, RW (2016). Antisense Oligonucleotide 
Therapy for Inherited Retinal Dystrophies. Adv Exp Med Biol 854: 517–524.
 40. Igreja, S, Clarke, LA, Botelho, HM, Marques, L and Amaral, MD (2016). Correction 
of a Cystic Fibrosis Splicing Mutation by Antisense Oligonucleotides. Hum Mutat 37: 
209–215.
 41. Skordis, LA, Dunckley, MG, Yue, B, Eperon, IC and Muntoni, F. (2003). Bifunctional 
antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates 
SMN2 gene expression in patient fibroblasts. Proceed Natl Acad Sci USA 100, 
4114–4119.
 42. Scaffidi, P and Misteli, T (2005). Reversal of the cellular phenotype in the premature aging 
disease Hutchinson-Gilford progeria syndrome. Nat Med 11: 440–445.
 43. Cirak, S, Feng, L, Anthony, K, Arechavala-Gomeza, V, Torelli, S, Sewry, C et al. (2012). 
Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy 
in Duchenne muscular dystrophy. Mol Ther 20: 462–467.
 44. Hua, Y, Sahashi, K, Hung, G, Rigo, F, Passini, MA, Bennett, CF et al. (2010). Antisense 
correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. 
Genes Dev 24: 1634–1644.
 45. Gérard, X, Perrault, I, Munnich, A, Kaplan, J and Rozet, JM (2015). Intravitreal injection of 
splice-switching oligonucleotides to manipulate splicing in retinal cells. Mol Ther Nucleic 
Acids 4: e250.
 46. Garanto, A, Chung, DC, Duijkers, L, Corral-Serrano, JC, Messchaert, M, Xiao, R et al. 
(2016). In vitro and in vivo rescue of aberrant splicing in CEP290-associated LCA by 
antisense oligonucleotide delivery. Hum Mol Genet (epub ahead of print).
 47. Gerard, X, Perrault, I, Hanein, S, Silva, E, Bigot, K, Defoort-Delhemmes, S et al. (2012). 
AON-mediated exon skipping restores ciliation in fibroblasts harboring the common Leber 
congenital amaurosis CEP290 mutation. Mol Ther Nucleic Acids 1: e29.
 48. Parfitt, DA, Lane, A, Ramsden, CM, Carr, AJ, Munro, PM, Jovanovic, K et al. (2016). 
Identification and correction of mechanisms underlying inherited blindness in human iPSC-
derived optic cups. Cell Stem Cell 18: 769–781.
 49. Miller, TM, Pestronk, A, David, W, Rothstein, J, Simpson, E, Appel, SH et al. (2013). An 
antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 
familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet 
Neurol 12: 435–442.
 50. Koo, T and Wood, MJ (2013). Clinical trials using antisense oligonucleotides in duchenne 
muscular dystrophy. Hum Gene Ther 24: 479–488.
 51. Goemans, NM, Tulinius, M, van den Akker, JT, Burm, BE, Ekhart, PF, Heuvelmans, N et al. 
(2011). Systemic administration of PRO051 in Duchenne’s muscular dystrophy. N Engl J 
Med 364: 1513–1522.
 52. Voit, T, Topaloglu, H, Straub, V, Muntoni, F, Deconinck, N, Campion, G et al. (2014). Safety 
and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND 
II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol 13: 
987–996.
 53. Flanigan, KM, Voit, T, Rosales, XQ, Servais, L, Kraus, JE, Wardell, C et al. (2014). 
Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects 
with Duchenne muscular dystrophy: results of a double-blind randomized clinical trial. 
Neuromuscul Disord 24: 16–24.
 54. Yu, FS and Hazlett, LD (2006). Toll-like receptors and the eye. Invest Ophthalmol Vis Sci 
47: 1255–1263.
 55. Kumar, MV, Nagineni, CN, Chin, MS, Hooks, JJ and Detrick, B (2004). Innate immunity 
in the retina: Toll-like receptor (TLR) signaling in human retinal pigment epithelial cells. J 
Neuroimmunol 153: 7–15.
 56. Richardt-Pargmann, D and Vollmer, J (2009). Stimulation of the immune system by 
therapeutic antisense oligodeoxynucleotides and small interfering RNAs via nucleic acid 
receptors. Ann N Y Acad Sci 1175: 40–54.
 57. Kole, R and Krieg, AM (2015). Exon skipping therapy for Duchenne muscular dystrophy. 
Adv Drug Deliv Rev 87: 104–107.
 58. Aartsma-Rus, A, Kaman, WE, Weij, R, den Dunnen, JT, van Ommen, GJ and 
van Deutekom, JC (2006). Exploring the frontiers of therapeutic exon skipping for 
Duchenne muscular dystrophy by double targeting within one or multiple exons. Mol Ther 
14: 401–407.
 59. Adams, AM, Harding, PL, Iversen, PL, Coleman, C, Fletcher, S and Wilton, SD (2007). 
Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: 
cocktails and chemistries. BMC Mol Biol 8: 57.
 60. Wilton, SD, Fall, AM, Harding, PL, McClorey, G, Coleman, C and Fletcher, S (2007). 
Antisense oligonucleotide-induced exon skipping across the human dystrophin gene 
transcript. Mol Ther 15: 1288–1296.
 61. Liu, X, Bulgakov, OV, Darrow, KN, Pawlyk, B, Adamian, M, Liberman, MC et al. (2007). 
Usherin is required for maintenance of retinal photoreceptors and normal development 
of cochlear hair cells. Proceed Natl Acad Sci USA 104, 4413–4418.
Molecular Therapy—Nucleic Acids
Antisense Oligonucleotide-based Splice Correction for USH2A-associated Retinal Degeneration
Slijkerman et al.
10
 62. Slijkerman, RW, Song, F, Astuti, GD, Huynen, MA, van Wijk, E, Stieger, K et al. (2015). 
The pros and cons of vertebrate animal models for functional and therapeutic research on 
inherited retinal dystrophies. Prog Retin Eye Res 48: 137–159.
 63. Wasfy, MM, Matsui, JI, Miller, J, Dowling, JE and Perkins, BD (2014). myosin 7aa(-/-) 
mutant zebrafish show mild photoreceptor degeneration and reduced electroretinographic 
responses. Exp Eye Res 122: 65–76.
 64. Phillips, JB, Blanco-Sanchez, B, Lentz, JJ, Tallafuss, A, Khanobdee, K, Sampath, S et al. 
(2011). Harmonin (Ush1c) is required in zebrafish Müller glial cells for photoreceptor 
synaptic development and function. Dis Model Mech 4: 786–800.
 65. Seiler, C, Finger-Baier, KC, Rinner, O, Makhankov, YV, Schwarz, H, Neuhauss, SC et al. 
(2005). Duplicated genes with split functions: independent roles of protocadherin15 
orthologues in zebrafish hearing and vision. Development 132: 615–623.
 66. Ebermann, I, Phillips, JB, Liebau, MC, Koenekoop, RK, Schermer, B, Lopez, I et al. (2010). 
PDZD7 is a modifier of retinal disease and a contributor to digenic Usher syndrome. J Clin 
Invest 120: 1812–1823.
 67. Garanto, A, Duijkers, L and Collin, RW (2015). Species-dependent splice recognition of a 
cryptic exon resulting from a recurrent intronic CEP290 mutation that causes congenital 
blindness. Int J Mol Sci 16: 5285–5298.
 68. Raghava, S, Hammond, M and Kompella, UB (2004). Periocular routes for retinal drug 
delivery. Expert Opin Drug Deliv 1: 99–114.
 69. Janoria, KG, Gunda, S, Boddu, SH and Mitra, AK (2007). Novel approaches to retinal drug 
delivery. Expert Opin Drug Deliv 4: 371–388.
 70. Falzarano, MS, Passarelli, C and Ferlini, A (2014). Nanoparticle delivery of antisense 
oligonucleotides and their application in the exon skipping strategy for Duchenne muscular 
dystrophy. Nucleic Acid Ther 24: 87–100.
 71. Wada, S, Urase, T, Hasegawa, Y, Ban, K, Sudani, A, Kawai, Y et al. (2014). Aib-containing 
peptide analogs: cellular uptake and utilization in oligonucleotide delivery. Bioorg Med 
Chem 22: 6776–6780.
 72. Gedicke-Hornung, C, Behrens-Gawlik, V, Reischmann, S, Geertz, B, Stimpel, D, 
Weinberger, F et al. (2013). Rescue of cardiomyopathy through U7snRNA-mediated exon 
skipping in Mybpc3-targeted knock-in mice. EMBO Mol Med 5: 1128–1145.
 73. Geib, T and Hertel, KJ (2009). Restoration of full-length SMN promoted by adenoviral 
vectors expressing RNA antisense oligonucleotides embedded in U7 snRNAs. PLoS One 
4: e8204.
 74. Goyenvalle, A, Vulin, A, Fougerousse, F, Leturcq, F, Kaplan, JC, Garcia, L et al. (2004). 
Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306: 
1796–1799.
 75. Dalkara, D, Kolstad, KD, Caporale, N, Visel, M, Klimczak, RR, Schaffer, DV et al. (2009). 
Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. 
Mol Ther 17: 2096–2102.
 76. Kotterman, MA, Yin, L, Strazzeri, JM, Flannery, JG, Merigan, WH and Schaffer, DV 
(2015). Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector 
gene delivery to non-human primates. Gene Ther 22: 116–126.
 77. Li, Q, Miller, R, Han, PY, Pang, J, Dinculescu, A, Chiodo, V et al. (2008). Intraocular route 
of AAV2 vector administration defines humoral immune response and therapeutic potential. 
Mol Vis 14: 1760–1769.
 78. Dalkara, D, Byrne, LC, Klimczak, RR, Visel, M, Yin, L, Merigan, WH et al. (2013). In 
vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene 
delivery from the vitreous. Sci Transl Med 5: 189ra76.
 79. Kremer, H, van Wijk, E, Märker, T, Wolfrum, U and Roepman, R (2006). Usher syndrome: 
molecular links of pathogenesis, proteins and pathways. Hum Mol Genet 15 Spec No 2: 
R262–R270.
 80. Reiners, J, van Wijk, E, Märker, T, Zimmermann, U, Jürgens, K, te Brinke, H et al. (2005). 
Scaffold protein harmonin (USH1C) provides molecular links between Usher syndrome 
type 1 and type 2. Hum Mol Genet 14: 3933–3943.
 81. Lentz, JJ, Jodelka, FM, Hinrich, AJ, McCaffrey, KE, Farris, HE, Spalitta, MJ et al. (2013). 
Rescue of hearing and vestibular function by antisense oligonucleotides in a mouse model 
of human deafness. Nat Med 19: 345–350.
 82. Reuter, JS and Mathews, DH (2010). RNAstructure: software for RNA secondary structure 
prediction and analysis. BMC Bioinformatics 11: 129.
 83. Yariz, KO, Duman, D, Seco, CZ, Dallman, J, Huang, M, Peters, TA et al. (2012). Mutations 
in OTOGL, encoding the inner ear protein otogelin-like, cause moderate sensorineural 
hearing loss. Am J Hum Genet 91: 872–882.
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivs 4.0 International 
License. The images or other third party material in this article are 
included in the article's Creative Commons license, unless indicated 
otherwise in the credit line; if the material is not included under the 
Creative Commons license, users will need to obtain permission 
from the license holder to reproduce the material. To view a copy of 
this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
© The Author(s) (2016)
Supplementary Information accompanies this paper on the Molecular Therapy–Nucleic Acids website (http://www.nature.com/mtna)
